19 July 2024
BELLUSCURA PLC
("Belluscura" or the "Company")
PDMR Award of Options
Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that the Company has today granted unapproved share options ("Options") of 4.0 million ordinary shares of 1 penny each in the Company ("Ordinary Shares") to Simon Neicheril, Chief Financial Officer.
The Options have been awarded upon the recommendation of the Company's Remuneration Committee.
The Options have an exercise price of 14.5 pence per share (being the closing mid-market price of the Ordinary Shares on 18 July 2024) and will expire 10 years from the date of grant.
The Options are subject to the following performance criteria; 2.0 million Options will vest when the price of the Ordinary Shares reaches 20p. The further 2.0 million Options will vest when the price of the Ordinary Shares reaches 25p. Each Option is exercisable into one Ordinary Share.
Upon a change in control of the Company, or an Offer for the Company's entire Share Capital, or termination of Mr. Neicheril's employment contract as a good leaver, all remaining unvested Options will vest immediately.
For further information please contact:
|
Belluscura plc |
Tel: +44 (0)20 3128 8100 |
|
Adam Reynolds, Chairman |
|
|
Robert Rauker, Chief Executive Officer |
|
|
|
|
|
|
|
|
SPARK Advisory Partners Limited - Nominated Adviser |
Tel: +44 (0)20 3368 3550 |
|
Neil Baldwin / Jade Bayat |
|
|
|
|
|
|
|
|
Dowgate Capital Limited - Broker |
Tel: +44 (0)20 3903 7715 |
|
Russell Cook / Nicholas Chambers |
|
|
|
|
|
|
|
|
MHP Group - Financial PR & Investor Relations |
Tel: +44 (0)20 3128 8100 |
|
Katie Hunt / Matthew Taylor |
email: Belluscura@mhpgroup.com |
|
|
|
About Belluscura plc (https://belluscura.com/)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Simon Neicheril |
||||
|
2 |
Reason for notification |
|||||
|
a) |
Position / status |
Chief Financial Officer |
||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Belluscura plc |
||||
|
b) |
LEI |
213800BRJQZE56XBPW94 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.01 each in Belluscura plc ISIN: GB00BD3B8Z11 |
||||
|
b) |
Nature of the transaction |
Grant of Options over Ordinary shares of £0.01 each
|
||||
|
c) |
Price(s) and volumes(s) |
|
||||
|
d) |
Aggregated information |
n/a |
||||
|
e) |
Date of the transaction |
19 July 2024 |
||||
|
f) |
Place of the transaction |
Outside a Trading Venue |
||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
